AOXG Company Description

Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People’s Republic of China.

The company’s principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain.

Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain.

The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010.

Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.

Aoxing Pharmaceutical Company, Inc.

Country	United States
Industry	Shell Companies
Sector	Financials
Employees	346
CEO	Zhenjiang Yue

Contact Details

Address: No. 2 Bojin Mansion Shijiazhuang, Florida Florida China
Phone	86 311 8961 8579
Website	axzyen.icm.cn

Stock Details

Ticker Symbol	AOXG
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	July - June
Reporting Currency	USD
ISIN Number	US03740A1060
SIC Code	2834

Key Executives

Name	Position
Zhenjiang Yue	Chairman and Chief Executive Officer
Guoan Zhang	Chief Accounting Officer and Senior Vice President of Finance